Cargando…
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
γ‐Secretase inhibitors (GSIs) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSIs against a broader panel of substrates, we demonstrate that clinical GSIs are pharm...
Autores principales: | Ran, Yong, Hossain, Fokhrul, Pannuti, Antonio, Lessard, Christian B, Ladd, Gabriela Z, Jung, Joo In, Minter, Lisa M, Osborne, Barbara A, Miele, Lucio, Golde, Todd E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494507/ https://www.ncbi.nlm.nih.gov/pubmed/28539479 http://dx.doi.org/10.15252/emmm.201607265 |
Ejemplares similares
-
γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
por: Lessard, Christian B., et al.
Publicado: (2020) -
Differential Inhibition of Signal Peptide Peptidase Family Members by Established γ-Secretase Inhibitors
por: Ran, Yong, et al.
Publicado: (2015) -
Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators
por: Jung, Joo In, et al.
Publicado: (2014) -
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses
por: Hossain, Fokhrul, et al.
Publicado: (2018) -
Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer
por: Hossain, Fokhrul, et al.
Publicado: (2023)